Search results

620 results

Sorted by Relevance . Sort by Date

  1. UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia (MTG26)

    Evidence-based recommendations on UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia (BHP)

  2. Virtual Touch Quantification to diagnose and monitor liver fibrosis in chronic hepatitis B and C (MTG27)

    Evidence-based recommendations on Virtual Touch Quantification for diagnosing and monitoring liver fibrosis in chronic Hepatitis B and C

  3. Spectra Optia for automatic red blood cell exchange in patients with sickle cell disease (MTG28)

    Evidence-based recommendations on Spectra Optia for automated red blood cell exchange in patients with sickle cell disease

  4. Parafricta Bootees and Undergarments to reduce skin breakdown in people with or at risk of pressure ulcers (MTG20)

    Evidence-based recommendations on the Parafricta Bootees and Undergarments to reduce the development or risk of pressure ulcers caused by skin breakdown

  5. Senza spinal cord stimulation system for delivering HF10 therapy to treat chronic neuropathic pain (MTG41)

    Evidence-based recommendations on the Senza spinal cord stimulation system for delivering HF10 therapy to treat chronic neuropathic pain

  6. ENDURALIFE powered CRT-D devices for treating heart failure (MTG33)

    Evidence-based recommendations on ENDURALIFE-powered cardiac resynchronisation therapy-defibrillator (CRT-D) devices for treating heart failure

  7. MiraQ for assessing graft flow during coronary artery bypass graft surgery (MTG8)

    Evidence-based recommendations on MiraQ for assessing graft flow during coronary artery bypass graft surgery

  8. PleurX peritoneal catheter drainage system for vacuum-assisted drainage of treatment-resistant, recurrent malignant ascites (MTG9)

    Evidence-based recommendations on PleurX peritoneal catheter drainage system for vacuum-assisted drainage of treatment-resistant, recurrent malignant ascites

  9. E‑vita open plus for treating complex aneurysms and dissections of the thoracic aorta (MTG16)

    Evidence-based recommendations on the E-vita open plus for treating complex aneurysms and dissections of the thoracic aorta

  10. The ReCell Spray‑On Skin system for treating skin loss, scarring and depigmentation after burn injury (MTG21)

    Evidence-based recommendations on the ReCell Spray-On Skin system for treating skin loss, scarring and depigmentation after burn injury

  11. Alpha Stim AID

    In development [GID-MT542] Expected publication date: 27 January 2021

  12. COVID-19 rapid guideline: managing symptoms (including at the end of life) in the community (NG163)

    The purpose of this guideline is to provide recommendations for managing COVID-19 symptoms for patients in the community, including at the end of life. It also includes recommendations about managing medicines for these patients, and protecting staff from infection.

  13. COVID-19 rapid guideline: community-based care of patients with chronic obstructive pulmonary disease (COPD) (NG168)

    The purpose of this guideline is to maximise the safety of patients with chronic obstructive pulmonary disease (COPD) during the COVID-19 pandemic, while protecting staff from infection. It will also enable services to make the best use of NHS resources.

  14. COVID-19 rapid guideline: critical care in adults (NG159)

    The purpose of this guideline is to maximise the safety of patients who need critical care during the COVID-19 pandemic, while protecting staff from infection. It will also enable services to make the best use of NHS resources.

  15. COVID-19 rapid guideline: rheumatological autoimmune, inflammatory and metabolic bone disorders (NG167)

    The purpose of this guideline is to maximise the safety of children and adults with rheumatological autoimmune, inflammatory and metabolic bone disorders during the COVID-19 pandemic, while protecting staff from infection. It also enables services to make the best use of NHS resources.

  16. COVID-19 rapid guideline: delivery of systemic anticancer treatments (NG161)

    The purpose of this guideline is to maximise the safety of patients with cancer and make the best use of NHS resources, while protecting staff from infection. It will also enable services to match the capacity for cancer treatment to patient needs if services become limited because of the COVID-19 pandemic.

  17. COVID-19 rapid guideline: acute kidney injury in hospital (NG175)

    The purpose of this guideline is to help healthcare professionals prevent, detect and manage acute kidney injury in adults in hospital with known or suspected COVID-19. This is important to improve outcomes and reduce the need for renal replacement therapy.

  18. COVID-19 rapid guideline: gastrointestinal and liver conditions treated with drugs affecting the immune response (NG172)

    The purpose of this guideline is to maximise the safety of children and adults who have gastrointestinal or liver conditions treated with drugs affecting the immune response during the COVID 19 pandemic. It also aims to protect staff from infection and enable services to make the best use of NHS resources.

  19. COVID-19 rapid guideline: delivery of radiotherapy (NG162)

    The purpose of this guideline is to maximise the safety of patients who need radiotherapy and make the best use of NHS resources, while protecting staff from infection. It will also enable services to match the capacity for radiotherapy to patient needs if services become limited because of the COVID-19 pandemic.

  20. COVID-19 rapid guideline: children and young people who are immunocompromised (NG174)

    The purpose of this guideline is to maximise the safety of children and young people who are immunocompromised during the COVID-19 pandemic. It also aims to protect staff from infection and enable services to make the best use of NHS resources.

  21. COVID-19 rapid guideline: dermatological conditions treated with drugs affecting the immune response (NG169)

    The purpose of this guideline is to maximise the safety of children and adults who have dermatological conditions treated with drugs affecting the immune response during the COVID-19 pandemic. It also aims to protect staff from infection and enable services to make the best use of NHS resources.

  22. COVID-19 rapid guideline: managing suspected or confirmed pneumonia in adults in the community (NG165)

    The purpose of this guideline is to ensure the best treatment for adults with suspected or confirmed pneumonia in the community during the COVID-19 pandemic and best use of NHS resources. We have withdrawn our guideline on diagnosing and managing pneumonia in adults until further notice. For general advice on managing COVID-19 symptoms, see the NICE COVID-19 rapid guideline on managing symptoms (including at the end of life) in the community .